Stock Track | AxoGen Soars 14.24% in Pre-market on Strong Q1 Earnings Beat and Upbeat Guidance
Stock Track
Apr 28
AxoGen's stock surged 14.24% in pre-market trading on Tuesday, following the release of its first-quarter 2026 financial results that exceeded analyst expectations.
The medical technology company reported quarterly revenue of $61.5 million, surpassing the IBES estimate of $57.7 million. The company also posted an adjusted EBITDA of $5.7 million and an adjusted net income of $4.1 million for the quarter, alongside a robust gross margin of 75.2%.
Investor sentiment was further bolstered by the company's forward-looking statements, which included a full-year revenue outlook of $270 million and an expected gross margin between 74% and 76% for 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.